Cargando…
Biomarker testing in oncology – Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL
In personalized medicine, predictive biomarker testing is the basis for an appropriate choice of therapy for patients with cancer. An important tool for laboratories to ensure accurate results is participation in external quality assurance (EQA) programs. Several providers offer predictive EQA progr...
Autores principales: | Dufraing, K., Fenizia, F., Torlakovic, E., Wolstenholme, N., Deans, Z. C., Rouleau, E., Vyberg, M., Parry, S., Schuuring, E., Dequeker, Elisabeth M. C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550230/ https://www.ncbi.nlm.nih.gov/pubmed/33047156 http://dx.doi.org/10.1007/s00428-020-02928-z |
Ejemplares similares
-
IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing
por: Deans, Zandra C., et al.
Publicado: (2019) -
Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL
por: Deans, Zandra C, et al.
Publicado: (2016) -
Molecular pathology testing for non-small cell lung cancer: an observational study of elements currently present in request forms and result reports and the opinion of different stakeholders
por: Dufraing, Kelly, et al.
Publicado: (2022) -
Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey
por: Deans, Zandra C., et al.
Publicado: (2017) -
Results of a worldwide external quality assessment of cfDNA testing in lung Cancer
por: Fairley, Jennifer A., et al.
Publicado: (2022)